Q-omics provides the consensus-scored ZNF516 profile across patient tissues and cancer cell-line models. ZNF516 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ZNF516 is differentially expressed in 8, with the highest sampling consensus in LIHC. Additionally, ZNF516 RNA expression shows 20,219 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and LIHC as cancer lineages where ZNF516 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF516 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF516 survival associations across molecular data types. ZNF516 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF516 RNA expression–survival associations across cancer types. High ZNF516 expression shows unfavorable associations in ACC and LIHC, but favorable associations in SCLC, BRCA, KIRC and UCEC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ZNF516 RNA expression.
This table summarizes ZNF516 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 5. The strongest signals are observed in LIHC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF516. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF516 shows lower tumor expression in BLCA, PRAD and UCEC and higher tumor expression in LIHC, CHOL and HNSC. The LIHC box plot shows higher ZNF516 RNA expression in tumor versus normal tissue (log2 FC = +0.860, t-test p < 0.001).
This table shows molecular features associated with ZNF516 in patient tissues and cancer cell lines. In patient samples, ZNF516 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF516 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
